Literature DB >> 2956883

Plasma concentrations of magnesium, lead, lithium, copper, and zinc in mentally retarded persons.

H H Bruhl, J Foni, Y H Lee, A Madow.   

Abstract

The metal magnesium and the trace elements lead, lithium, copper, and zinc were determined by atomic absorption spectrophotometry in the plasma of 107 residents with different types of mental retardation at a state institution in Minnesota. Twenty-six staff volunteers and 29 residents with psychosocial mental retardation served as control subjects. Plasma magnesium concentrations were normal in all retarded subjects. Lead and lithium concentrations were below detection levels in all retarded and nonretarded subjects. Low copper concentrations were found in the plasma of retarded dwarfs and of male microcephalic subjects. The most significant finding was hypozincemia in 49 subjects with Down syndrome of both sexes and all ages. Because this finding was limited to residents with Down syndrome, a nutritional deficiency is most unlikely. The possible etiological factors of hypozincemia in Down syndrome were discussed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2956883

Source DB:  PubMed          Journal:  Am J Ment Defic        ISSN: 0002-9351


  3 in total

1.  Changed serum trace element profile in Down's syndrome.

Authors:  J Kadrabová; A Madáric; M Sustrová; E Ginter
Journal:  Biol Trace Elem Res       Date:  1996-09       Impact factor: 3.738

Review 2.  Systematic review and meta-analysis shows a specific micronutrient profile in people with Down Syndrome: Lower blood calcium, selenium and zinc, higher red blood cell copper and zinc, and higher salivary calcium and sodium.

Authors:  Amene Saghazadeh; Maryam Mahmoudi; Atefeh Dehghani Ashkezari; Nooshin Oliaie Rezaie; Nima Rezaei
Journal:  PLoS One       Date:  2017-04-19       Impact factor: 3.240

Review 3.  Glycogen Synthase Kinase-3 Inhibitors: Preclinical and Clinical Focus on CNS-A Decade Onward.

Authors:  Sara Melisa Arciniegas Ruiz; Hagit Eldar-Finkelman
Journal:  Front Mol Neurosci       Date:  2022-01-21       Impact factor: 5.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.